Retatrutide: arguable the most effective metabolic drug ever developed. Full steam for LLY
Surprised how little attention Retatrutide is getting, even though it has the potential to be the most effective obesity and metabolic disease drug ever developed. Eli Lilly is leading the market with Mounjaro and Zepbound, but retatrutide, their next generation triple agonist targeting GLP 1, GIP, and glucagon receptors, could surpass both. I work in […]
UPSC Key: Roadmap on de-escalation, GLP-1 drugs, and Coastline paradox
Post Content
Dietitian Who Lost 60 Pounds With GLP-1 Drug Reveals Foods to Avoid and Prioritize
Hims & Hers (HIMS) Jumps 6.76% Anew as Investors Cheer Weight Loss Drug Fight
Hims & Hers Health, Inc. (NYSE:HIMS) is one of the 10 Stocks Leave Wall Street Stunned. Hims & Hers extended its rally for the second day on Friday, adding 6.76 percent to close at $49.41 apiece after its chief executive’s reaffirmation that the company will continue to offer cheaper compounded versions of GLP-1 weight-loss drugs, […]
Why Thousands Are Risking DIY Weight-Loss Injections
High prices and limited insurance coverage have driven a growing number of Americans to seek weight-loss solutions outside the doctor’s office and the law. Online forums, encrypted chat groups, and underground vendors are fueling a gray market for injectable obesity drugs, often sourced from unregulated suppliers overseas. At the heart of this trend are popular […]
768-P: Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Motility-Related Gastrointestinal Adverse Events—A Cohort Study
Introduction and Objective: To assess if glucagon-like peptide-1 receptor agonist (GLP-1 RA) compared with sodium-glucose cotransporter 2 inhibitors (SGLT-2i), is associated with an increased risk of motility-related gastrointestinal (GI) adverse events.Methods: From two US commercial healthcare databases, we used 1-1 propensity score matching on >150 potential confounders to identify a cohort of adults with type […]
750-P: ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose Study
Introduction and Objective: ASC30 is an oral GLP-1R biased small molecule agonist without β-arrestin recruitment, discovered and developed in-house at Ascletis. ASC30 has unique and differentiated properties that enable the administration of one small molecule as both a once-monthly subcutaneous injection and a once-daily oral tablet. The current study assessed safety, tolerability and pharmacokinetics of […]
758-P: Titration to Maintenance Doses of GLP-1R Agonists for Overweight and Obesity Is Suboptimal for Majority of Patients—Evidence from a Real-World Claims Dataset
Introduction and Objective: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) represent a paradigm shift in treating obesity. The substantial weight loss observed in clinical trials improves weight-related comorbidities. However, weight loss reported in the real world has been less than that seen in clinical trials. One hypothesis for this gap is that patients may not complete the […]
292-OR: Oral Semaglutide and Cardiovascular Outcomes by Baseline A1C and BMI in People with Type 2 Diabetes in the SOUL Trial
Introduction and Objective: In SOUL (NCT03914326), oral semaglutide (sema) 14 mg QD, a GLP-1 receptor agonist, reduced major adverse cardiovascular (CV) event (MACE) risk by 14%. GLP-1RAs are routinely prescribed to reduce A1c and BMI in type 2 diabetes (T2D). Whether the CV benefits of oral sema are influenced by baseline A1c or BMI is […]
How GLP-1 drugs like semaglutide have revolutionised obesity treatment
Post Content